Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Intestinal Neoplasms 3Gastrointestinal Neoplasms 3Gastrointestinal Diseases 3Colorectal Neoplasms 3Rectal Neoplasms 2Digestive System Neoplasms 2Rectal Diseases 1Osteosarcoma 1Neoplasms by Site 1Neoplasms 1Intestinal Diseases 1Digestive System Diseases 1Colonic Neoplasms 1

Interventions

Pemetrexed 9Nivolumab 8Cisplatin 8Carboplatin 8pembrolizumab 7130-nm albumin-bound paclitaxel 7Gemcitabine 6padeliporfin 5durvalumab 5Paclitaxel 5Bevacizumab 5palbociclib 4napabucasin 4atezolizumab 4Irinotecan 4Fulvestrant 4Fluorouracil 4Drug Therapy 4Cyclophosphamide 4ribociclib 3osimertinib 3cobimetinib 3alectinib 3abemaciclib 3Trastuzumab 3Sunitinib 3Radiosurgery 3Mitomycin 3Docetaxel 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × 5,10-methylenetetrahydrofolic acid × Clear all
NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡